SARS-CoV-2 Treatment Approaches: Numerous Options, No Certainty for a Versatile Virus.
Identifieur interne : 000C66 ( Main/Exploration ); précédent : 000C65; suivant : 000C67SARS-CoV-2 Treatment Approaches: Numerous Options, No Certainty for a Versatile Virus.
Auteurs : Simona Iacob [Roumanie] ; Diana Gabriela Iacob [Roumanie]Source :
- Frontiers in pharmacology [ 1663-9812 ] ; 2020.
Abstract
SARS-CoV-2 is the most recent coronavirus which crossed the species barrier in 2019 and provoked a still ongoing and dangerous pandemic known as coronavirus disease 2019 (COVID-19). The SARS-CoV-2 infection has triggered an impressive amount of clinical and experimental studies to identify an effective and safe therapy to stop the pandemic spread. Hence, numerous trials and studies have scrutinized the analogies between SARS-CoV-2 and other corona viruses or the host-virus interactions and their similarities with immune system disorders. Still, the pathogenic mechanisms behind SARS-CoV-2 have been partially deciphered and the current therapies have not yet met the initial enthusiastic expectations. So far COVID-19 therapies have targeted various pathogenic mechanisms, namely the neutralization of ACE2 receptors or SARS-CoV-2 spike protein epitopes, the disruption of the endocytic pathways using hydroxychloroquine, arbidol, or anti-Janus kinase inhibitors, the inhibition of RNA-dependent RNA polymerase using nucleotide analogues such as remdesivir, immunosuppressive drugs or molecules acting on the immune response (corticoids, interferons, monoclonal antibodies against inflammatory cytokines, mesenchymal stem cells) and convalescent plasma administration together with numerous drugs with unproven effect against SARS-CoV-2 but with potential antiviral activities (antiretrovirals, antimalarial drugs, antibiotics, etc.). Nevertheless, these therapies have been associated with side effects and contradictory results. At the same time a specific SARS-CoV-2 vaccine is a long-term solution requiring clinical validation and important investments together with appropriate strategies to promote the confidence in the safety of the new vaccine. The article revises the current state of SARS-CoV-2 therapeutic options but advises towards a more cautious and individualized treatment approach centred on the clinical features, immune particularities, and the risk-benefit balance.
DOI: 10.3389/fphar.2020.01224
PubMed: 32982720
PubMed Central: PMC7479232
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">SARS-CoV-2 Treatment Approaches: Numerous Options, No Certainty for a Versatile Virus.</title><author><name sortKey="Iacob, Simona" sort="Iacob, Simona" uniqKey="Iacob S" first="Simona" last="Iacob">Simona Iacob</name><affiliation wicri:level="1"><nlm:affiliation>Infectious Diseases Department, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.</nlm:affiliation><country xml:lang="fr">Roumanie</country><wicri:regionArea>Infectious Diseases Department, Carol Davila University of Medicine and Pharmacy, Bucharest</wicri:regionArea><wicri:noRegion>Bucharest</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:affiliation>Infectious Diseases Department, National Institute of Infectious Diseases "Prof dr. Matei Bals", Bucharest, Romania.</nlm:affiliation><country xml:lang="fr">Roumanie</country><wicri:regionArea>Infectious Diseases Department, National Institute of Infectious Diseases "Prof dr. Matei Bals", Bucharest</wicri:regionArea><wicri:noRegion>Bucharest</wicri:noRegion></affiliation></author><author><name sortKey="Iacob, Diana Gabriela" sort="Iacob, Diana Gabriela" uniqKey="Iacob D" first="Diana Gabriela" last="Iacob">Diana Gabriela Iacob</name><affiliation wicri:level="1"><nlm:affiliation>Infectious Diseases Department, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.</nlm:affiliation><country xml:lang="fr">Roumanie</country><wicri:regionArea>Infectious Diseases Department, Carol Davila University of Medicine and Pharmacy, Bucharest</wicri:regionArea><wicri:noRegion>Bucharest</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:affiliation>Infectious Diseases Department, Bucharest Emergency University Hospital, Bucharest, Romania.</nlm:affiliation><country xml:lang="fr">Roumanie</country><wicri:regionArea>Infectious Diseases Department, Bucharest Emergency University Hospital, Bucharest</wicri:regionArea><wicri:noRegion>Bucharest</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32982720</idno><idno type="pmid">32982720</idno><idno type="doi">10.3389/fphar.2020.01224</idno><idno type="pmc">PMC7479232</idno><idno type="wicri:Area/Main/Corpus">000B40</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000B40</idno><idno type="wicri:Area/Main/Curation">000B40</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000B40</idno><idno type="wicri:Area/Main/Exploration">000B40</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">SARS-CoV-2 Treatment Approaches: Numerous Options, No Certainty for a Versatile Virus.</title><author><name sortKey="Iacob, Simona" sort="Iacob, Simona" uniqKey="Iacob S" first="Simona" last="Iacob">Simona Iacob</name><affiliation wicri:level="1"><nlm:affiliation>Infectious Diseases Department, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.</nlm:affiliation><country xml:lang="fr">Roumanie</country><wicri:regionArea>Infectious Diseases Department, Carol Davila University of Medicine and Pharmacy, Bucharest</wicri:regionArea><wicri:noRegion>Bucharest</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:affiliation>Infectious Diseases Department, National Institute of Infectious Diseases "Prof dr. Matei Bals", Bucharest, Romania.</nlm:affiliation><country xml:lang="fr">Roumanie</country><wicri:regionArea>Infectious Diseases Department, National Institute of Infectious Diseases "Prof dr. Matei Bals", Bucharest</wicri:regionArea><wicri:noRegion>Bucharest</wicri:noRegion></affiliation></author><author><name sortKey="Iacob, Diana Gabriela" sort="Iacob, Diana Gabriela" uniqKey="Iacob D" first="Diana Gabriela" last="Iacob">Diana Gabriela Iacob</name><affiliation wicri:level="1"><nlm:affiliation>Infectious Diseases Department, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.</nlm:affiliation><country xml:lang="fr">Roumanie</country><wicri:regionArea>Infectious Diseases Department, Carol Davila University of Medicine and Pharmacy, Bucharest</wicri:regionArea><wicri:noRegion>Bucharest</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:affiliation>Infectious Diseases Department, Bucharest Emergency University Hospital, Bucharest, Romania.</nlm:affiliation><country xml:lang="fr">Roumanie</country><wicri:regionArea>Infectious Diseases Department, Bucharest Emergency University Hospital, Bucharest</wicri:regionArea><wicri:noRegion>Bucharest</wicri:noRegion></affiliation></author></analytic><series><title level="j">Frontiers in pharmacology</title><idno type="ISSN">1663-9812</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">SARS-CoV-2 is the most recent coronavirus which crossed the species barrier in 2019 and provoked a still ongoing and dangerous pandemic known as coronavirus disease 2019 (COVID-19). The SARS-CoV-2 infection has triggered an impressive amount of clinical and experimental studies to identify an effective and safe therapy to stop the pandemic spread. Hence, numerous trials and studies have scrutinized the analogies between SARS-CoV-2 and other corona viruses or the host-virus interactions and their similarities with immune system disorders. Still, the pathogenic mechanisms behind SARS-CoV-2 have been partially deciphered and the current therapies have not yet met the initial enthusiastic expectations. So far COVID-19 therapies have targeted various pathogenic mechanisms, namely the neutralization of ACE2 receptors or SARS-CoV-2 spike protein epitopes, the disruption of the endocytic pathways using hydroxychloroquine, arbidol, or anti-Janus kinase inhibitors, the inhibition of RNA-dependent RNA polymerase using nucleotide analogues such as remdesivir, immunosuppressive drugs or molecules acting on the immune response (corticoids, interferons, monoclonal antibodies against inflammatory cytokines, mesenchymal stem cells) and convalescent plasma administration together with numerous drugs with unproven effect against SARS-CoV-2 but with potential antiviral activities (antiretrovirals, antimalarial drugs, antibiotics, etc.). Nevertheless, these therapies have been associated with side effects and contradictory results. At the same time a specific SARS-CoV-2 vaccine is a long-term solution requiring clinical validation and important investments together with appropriate strategies to promote the confidence in the safety of the new vaccine. The article revises the current state of SARS-CoV-2 therapeutic options but advises towards a more cautious and individualized treatment approach centred on the clinical features, immune particularities, and the risk-benefit balance.</div></front></TEI><pubmed><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">32982720</PMID><DateRevised><Year>2020</Year><Month>10</Month><Day>01</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1663-9812</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><PubDate><Year>2020</Year></PubDate></JournalIssue><Title>Frontiers in pharmacology</Title><ISOAbbreviation>Front Pharmacol</ISOAbbreviation></Journal><ArticleTitle>SARS-CoV-2 Treatment Approaches: Numerous Options, No Certainty for a Versatile Virus.</ArticleTitle><Pagination><MedlinePgn>1224</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3389/fphar.2020.01224</ELocationID><Abstract><AbstractText>SARS-CoV-2 is the most recent coronavirus which crossed the species barrier in 2019 and provoked a still ongoing and dangerous pandemic known as coronavirus disease 2019 (COVID-19). The SARS-CoV-2 infection has triggered an impressive amount of clinical and experimental studies to identify an effective and safe therapy to stop the pandemic spread. Hence, numerous trials and studies have scrutinized the analogies between SARS-CoV-2 and other corona viruses or the host-virus interactions and their similarities with immune system disorders. Still, the pathogenic mechanisms behind SARS-CoV-2 have been partially deciphered and the current therapies have not yet met the initial enthusiastic expectations. So far COVID-19 therapies have targeted various pathogenic mechanisms, namely the neutralization of ACE2 receptors or SARS-CoV-2 spike protein epitopes, the disruption of the endocytic pathways using hydroxychloroquine, arbidol, or anti-Janus kinase inhibitors, the inhibition of RNA-dependent RNA polymerase using nucleotide analogues such as remdesivir, immunosuppressive drugs or molecules acting on the immune response (corticoids, interferons, monoclonal antibodies against inflammatory cytokines, mesenchymal stem cells) and convalescent plasma administration together with numerous drugs with unproven effect against SARS-CoV-2 but with potential antiviral activities (antiretrovirals, antimalarial drugs, antibiotics, etc.). Nevertheless, these therapies have been associated with side effects and contradictory results. At the same time a specific SARS-CoV-2 vaccine is a long-term solution requiring clinical validation and important investments together with appropriate strategies to promote the confidence in the safety of the new vaccine. The article revises the current state of SARS-CoV-2 therapeutic options but advises towards a more cautious and individualized treatment approach centred on the clinical features, immune particularities, and the risk-benefit balance.</AbstractText><CopyrightInformation>Copyright © 2020 Iacob and Iacob.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Iacob</LastName><ForeName>Simona</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Infectious Diseases Department, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Infectious Diseases Department, National Institute of Infectious Diseases "Prof dr. Matei Bals", Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iacob</LastName><ForeName>Diana Gabriela</ForeName><Initials>DG</Initials><AffiliationInfo><Affiliation>Infectious Diseases Department, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Infectious Diseases Department, Bucharest Emergency University Hospital, Bucharest, Romania.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>08</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Pharmacol</MedlineTA><NlmUniqueID>101548923</NlmUniqueID><ISSNLinking>1663-9812</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">angiotensin-converting enzyme 2 receptors</Keyword><Keyword MajorTopicYN="N">endocytosis</Keyword><Keyword MajorTopicYN="N">immune response</Keyword><Keyword MajorTopicYN="N">mesenchymal stem cells</Keyword><Keyword MajorTopicYN="N">monoclonal antibodies</Keyword><Keyword MajorTopicYN="N">therapeutic targets</Keyword><Keyword MajorTopicYN="N">vaccine</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>04</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>07</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>9</Month><Day>28</Day><Hour>5</Hour><Minute>39</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>9</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>9</Month><Day>29</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32982720</ArticleId><ArticleId IdType="doi">10.3389/fphar.2020.01224</ArticleId><ArticleId IdType="pmc">PMC7479232</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Antimicrob Chemother. 2020 Jul 1;75(7):2013-2014</Citation><ArticleIdList><ArticleId IdType="pubmed">32417899</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Chemother. 2020 Jun;26(6):625-632</Citation><ArticleIdList><ArticleId IdType="pubmed">32362440</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Regul Homeost Agents. 2020 Mar 14;34(2):327-331</Citation><ArticleIdList><ArticleId IdType="pubmed">32171193</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Infect Dis. 2020 May;20(5):565-574</Citation><ArticleIdList><ArticleId IdType="pubmed">32213337</ArticleId></ArticleIdList></Reference><Reference><Citation>Gene Ther. 2008 May;15(10):730-8</Citation><ArticleIdList><ArticleId IdType="pubmed">18401438</ArticleId></ArticleIdList></Reference><Reference><Citation>Emerg Microbes Infect. 2020 Dec;9(1):382-385</Citation><ArticleIdList><ArticleId IdType="pubmed">32065055</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2020 Mar;579(7798):270-273</Citation><ArticleIdList><ArticleId IdType="pubmed">32015507</ArticleId></ArticleIdList></Reference><Reference><Citation>Crit Care. 2020 Mar 18;24(1):108</Citation><ArticleIdList><ArticleId IdType="pubmed">32188484</ArticleId></ArticleIdList></Reference><Reference><Citation>Diabetes. 2010 Dec;59(12):2994-6</Citation><ArticleIdList><ArticleId IdType="pubmed">21115782</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2020 May 7;382(19):1787-1799</Citation><ArticleIdList><ArticleId IdType="pubmed">32187464</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Invest. 2020 Jun 1;130(6):2757-2765</Citation><ArticleIdList><ArticleId IdType="pubmed">32254064</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2012 May 17;366(20):1881-90</Citation><ArticleIdList><ArticleId IdType="pubmed">22591294</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ Glob Health. 2020 Jun;5(6):</Citation><ArticleIdList><ArticleId IdType="pubmed">32532758</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Pharm Sin B. 2020 May;10(5):766-788</Citation><ArticleIdList><ArticleId IdType="pubmed">32292689</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Invest. 2019 Jul 29;129(9):3625-3639</Citation><ArticleIdList><ArticleId IdType="pubmed">31355779</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2020 May 9;395(10235):1517-1520</Citation><ArticleIdList><ArticleId IdType="pubmed">32311318</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Diabetol. 2010 Sep;47(3):193-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19333547</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2020 Jun 18;382(25):2441-2448</Citation><ArticleIdList><ArticleId IdType="pubmed">32356628</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2020 May 30;395(10238):1695-1704</Citation><ArticleIdList><ArticleId IdType="pubmed">32401715</ArticleId></ArticleIdList></Reference><Reference><Citation>CMAJ. 2020 Apr 27;192(17):E450-E453</Citation><ArticleIdList><ArticleId IdType="pubmed">32269021</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Infect Dis. 2020 Aug;97:7-10</Citation><ArticleIdList><ArticleId IdType="pubmed">32479865</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Immunol. 2019 Nov 15;10:2679</Citation><ArticleIdList><ArticleId IdType="pubmed">31803190</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Host Microbe. 2016 Feb 10;19(2):181-93</Citation><ArticleIdList><ArticleId IdType="pubmed">26867177</ArticleId></ArticleIdList></Reference><Reference><Citation>FEBS Lett. 2002 Dec 4;532(1-2):107-10</Citation><ArticleIdList><ArticleId IdType="pubmed">12459472</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2020 Aug 15;396(10249):467-478</Citation><ArticleIdList><ArticleId IdType="pubmed">32702298</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Heart J. 2020 May 14;41(19):1804-1806</Citation><ArticleIdList><ArticleId IdType="pubmed">32293672</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Cell. 2020 May 21;78(4):779-784.e5</Citation><ArticleIdList><ArticleId IdType="pubmed">32362314</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2007 Aug;81(16):8722-9</Citation><ArticleIdList><ArticleId IdType="pubmed">17522231</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Res. 2020 Mar;30(3):269-271</Citation><ArticleIdList><ArticleId IdType="pubmed">32020029</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Commun. 2020 May 4;11(1):2251</Citation><ArticleIdList><ArticleId IdType="pubmed">32366817</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2020 Jul 28;71(15):732-739</Citation><ArticleIdList><ArticleId IdType="pubmed">32150618</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Transl Med. 2017 Jun 28;9(396):</Citation><ArticleIdList><ArticleId IdType="pubmed">28659436</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Biol Sci. 2020 Mar 15;16(10):1724-1731</Citation><ArticleIdList><ArticleId IdType="pubmed">32226290</ArticleId></ArticleIdList></Reference><Reference><Citation>Microb Pathog. 2020 Feb;139:103919</Citation><ArticleIdList><ArticleId IdType="pubmed">31830579</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2020 Feb 15;395(10223):e30-e31</Citation><ArticleIdList><ArticleId IdType="pubmed">32032529</ArticleId></ArticleIdList></Reference><Reference><Citation>Emerg Microbes Infect. 2020 Dec;9(1):558-570</Citation><ArticleIdList><ArticleId IdType="pubmed">32172672</ArticleId></ArticleIdList></Reference><Reference><Citation>J Thorac Dis. 2019 May;11(Suppl 9):S1329-S1332</Citation><ArticleIdList><ArticleId IdType="pubmed">31245124</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect. 2020 Jul;81(1):e1-e5</Citation><ArticleIdList><ArticleId IdType="pubmed">32171872</ArticleId></ArticleIdList></Reference><Reference><Citation>JCI Insight. 2019 Feb 21;4(4):</Citation><ArticleIdList><ArticleId IdType="pubmed">30830861</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2011 Dec;85(23):12201-15</Citation><ArticleIdList><ArticleId IdType="pubmed">21937658</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2020 May 16;395(10236):1569-1578</Citation><ArticleIdList><ArticleId IdType="pubmed">32423584</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2012 Jun;86(12):6537-45</Citation><ArticleIdList><ArticleId IdType="pubmed">22496216</ArticleId></ArticleIdList></Reference><Reference><Citation>Stem Cells Transl Med. 2020 Sep;9(9):1007-1022</Citation><ArticleIdList><ArticleId IdType="pubmed">32472653</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2020 May 28;181(5):1016-1035.e19</Citation><ArticleIdList><ArticleId IdType="pubmed">32413319</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2002 Jun 20;417(6891):822-8</Citation><ArticleIdList><ArticleId IdType="pubmed">12075344</ArticleId></ArticleIdList></Reference><Reference><Citation>Intensive Care Med. 2020 Apr;46(4):586-590</Citation><ArticleIdList><ArticleId IdType="pubmed">32125455</ArticleId></ArticleIdList></Reference><Reference><Citation>Stem Cells. 2010 Dec;28(12):2229-38</Citation><ArticleIdList><ArticleId IdType="pubmed">20945332</ArticleId></ArticleIdList></Reference><Reference><Citation>Crit Care. 2017 Sep 7;21(1):234</Citation><ArticleIdList><ArticleId IdType="pubmed">28877748</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunology. 1993 Sep;80(1):127-33</Citation><ArticleIdList><ArticleId IdType="pubmed">8244453</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Pharmacol. 2014 Aug;171(15):3595-603</Citation><ArticleIdList><ArticleId IdType="pubmed">24697653</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2020 May 8;368(6491):630-633</Citation><ArticleIdList><ArticleId IdType="pubmed">32245784</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2012;7(11):e50366</Citation><ArticleIdList><ArticleId IdType="pubmed">23185609</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Biol Sci. 2020 Mar 15;16(10):1718-1723</Citation><ArticleIdList><ArticleId IdType="pubmed">32226289</ArticleId></ArticleIdList></Reference><Reference><Citation>Transfusion. 2011 Feb;51(2):338-43</Citation><ArticleIdList><ArticleId IdType="pubmed">20723173</ArticleId></ArticleIdList></Reference><Reference><Citation>Cytokine. 2015 Oct;75(2):261-71</Citation><ArticleIdList><ArticleId IdType="pubmed">26113402</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2020 Mar 17;94(7):</Citation><ArticleIdList><ArticleId IdType="pubmed">31996437</ArticleId></ArticleIdList></Reference><Reference><Citation>Cochrane Database Syst Rev. 2020 Jul 10;7:CD013600</Citation><ArticleIdList><ArticleId IdType="pubmed">32648959</ArticleId></ArticleIdList></Reference><Reference><Citation>EClinicalMedicine. 2020 Jun 20;24:100418</Citation><ArticleIdList><ArticleId IdType="pubmed">32766537</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Netw Open. 2020 Apr 24;3(4):e208857</Citation><ArticleIdList><ArticleId IdType="pubmed">32330277</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pathol. 2004 Jun;203(2):631-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15141377</ArticleId></ArticleIdList></Reference><Reference><Citation>Aging Dis. 2020 Mar 9;11(2):216-228</Citation><ArticleIdList><ArticleId IdType="pubmed">32257537</ArticleId></ArticleIdList></Reference><Reference><Citation>mBio. 2018 Mar 6;9(2):</Citation><ArticleIdList><ArticleId IdType="pubmed">29511076</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2020 Aug 21;369(6506):956-963</Citation><ArticleIdList><ArticleId IdType="pubmed">32540903</ArticleId></ArticleIdList></Reference><Reference><Citation>Antimicrob Agents Chemother. 2016 Oct 21;60(11):6532-6539</Citation><ArticleIdList><ArticleId IdType="pubmed">27550352</ArticleId></ArticleIdList></Reference><Reference><Citation>Future Virol. 2019 Apr;14(4):275-286</Citation><ArticleIdList><ArticleId IdType="pubmed">32201500</ArticleId></ArticleIdList></Reference><Reference><Citation>Chem Phys Lett. 2020 Jul;750:137489</Citation><ArticleIdList><ArticleId IdType="pubmed">32313296</ArticleId></ArticleIdList></Reference><Reference><Citation>Semin Immunopathol. 2017 Jul;39(5):529-539</Citation><ArticleIdList><ArticleId IdType="pubmed">28466096</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Infect Dis. 2020 Apr;20(4):400-402</Citation><ArticleIdList><ArticleId IdType="pubmed">32113509</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Nephrol. 2018 Aug;14(8):493-507</Citation><ArticleIdList><ArticleId IdType="pubmed">29895977</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2005 Feb 15;105(4):1815-22</Citation><ArticleIdList><ArticleId IdType="pubmed">15494428</ArticleId></ArticleIdList></Reference><Reference><Citation>Antiviral Res. 2020 Apr;176:104742</Citation><ArticleIdList><ArticleId IdType="pubmed">32057769</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Antimicrob Agents. 2020 Aug;56(2):106023</Citation><ArticleIdList><ArticleId IdType="pubmed">32450201</ArticleId></ArticleIdList></Reference><Reference><Citation>Virol J. 2005 Aug 22;2:69</Citation><ArticleIdList><ArticleId IdType="pubmed">16115318</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Immunol. 2020 Sep;218:108517</Citation><ArticleIdList><ArticleId IdType="pubmed">32585295</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2020 May 19;117(20):10970-10975</Citation><ArticleIdList><ArticleId IdType="pubmed">32350134</ArticleId></ArticleIdList></Reference><Reference><Citation>Rheumatology (Oxford). 2006 Jun;45(6):703-10</Citation><ArticleIdList><ArticleId IdType="pubmed">16418198</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2020 Feb 15;395(10223):497-506</Citation><ArticleIdList><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2012;7(4):e35421</Citation><ArticleIdList><ArticleId IdType="pubmed">22536382</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2020 Apr 17;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32301997</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Vaccin Immunother. 2016 Sep;12(9):2351-6</Citation><ArticleIdList><ArticleId IdType="pubmed">27269431</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Respir Med. 2020 Jun;8(6):e46-e47</Citation><ArticleIdList><ArticleId IdType="pubmed">32353251</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2020 Jun 18;382(25):2411-2418</Citation><ArticleIdList><ArticleId IdType="pubmed">32379955</ArticleId></ArticleIdList></Reference><Reference><Citation>Intern Emerg Med. 2020 Aug;15(5):759-766</Citation><ArticleIdList><ArticleId IdType="pubmed">32430651</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2010 Feb;84(3):1289-301</Citation><ArticleIdList><ArticleId IdType="pubmed">19906920</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunohorizons. 2020 Feb 21;4(2):93-107</Citation><ArticleIdList><ArticleId IdType="pubmed">32086319</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Commun. 2020 Feb 26;11(1):1058</Citation><ArticleIdList><ArticleId IdType="pubmed">32103002</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2005 Aug;11(8):875-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16007097</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Respir Med. 2020 Apr;8(4):e21</Citation><ArticleIdList><ArticleId IdType="pubmed">32171062</ArticleId></ArticleIdList></Reference><Reference><Citation>Crit Care Clin. 2018 Apr;34(2):299-311</Citation><ArticleIdList><ArticleId IdType="pubmed">29482908</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2020 May 27;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32459919</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Intern Med. 2020 Jul 1;180(7):934-943</Citation><ArticleIdList><ArticleId IdType="pubmed">32167524</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2020 Jun 11;382(24):2327-2336</Citation><ArticleIdList><ArticleId IdType="pubmed">32275812</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Infect Dis. 2003 Nov;3(11):722-7</Citation><ArticleIdList><ArticleId IdType="pubmed">14592603</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2020 Apr 16;181(2):271-280.e8</Citation><ArticleIdList><ArticleId IdType="pubmed">32142651</ArticleId></ArticleIdList></Reference><Reference><Citation>Antiviral Res. 2020 Jun;178:104791</Citation><ArticleIdList><ArticleId IdType="pubmed">32275914</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2020 Jul 17;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32678530</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2020 May 14;181(4):905-913.e7</Citation><ArticleIdList><ArticleId IdType="pubmed">32333836</ArticleId></ArticleIdList></Reference><Reference><Citation>Asian Pac J Allergy Immunol. 2020 Mar;38(1):1-9</Citation><ArticleIdList><ArticleId IdType="pubmed">32105090</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Microbiol Infect. 2020 Jul;26(7):917-921</Citation><ArticleIdList><ArticleId IdType="pubmed">32344167</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2020 Feb 17;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32065831</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2004 Feb 24;101(8):2536-41</Citation><ArticleIdList><ArticleId IdType="pubmed">14983044</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2020 Jul;583(7816):459-468</Citation><ArticleIdList><ArticleId IdType="pubmed">32353859</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2020 May;26(5):681-687</Citation><ArticleIdList><ArticleId IdType="pubmed">32327758</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Mol Sci. 2020 Apr 10;21(7):</Citation><ArticleIdList><ArticleId IdType="pubmed">32290293</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2020 May;581(7807):215-220</Citation><ArticleIdList><ArticleId IdType="pubmed">32225176</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Antimicrob Agents. 2020 Jul;56(1):105949</Citation><ArticleIdList><ArticleId IdType="pubmed">32205204</ArticleId></ArticleIdList></Reference><Reference><Citation>Adv Virus Res. 2005;64:165-230</Citation><ArticleIdList><ArticleId IdType="pubmed">16139595</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Death Differ. 2020 May;27(5):1451-1454</Citation><ArticleIdList><ArticleId IdType="pubmed">32205856</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Immunol. 2018 Sep 27;9:2147</Citation><ArticleIdList><ArticleId IdType="pubmed">30319615</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Roumanie</li></country></list><tree><country name="Roumanie"><noRegion><name sortKey="Iacob, Simona" sort="Iacob, Simona" uniqKey="Iacob S" first="Simona" last="Iacob">Simona Iacob</name></noRegion><name sortKey="Iacob, Diana Gabriela" sort="Iacob, Diana Gabriela" uniqKey="Iacob D" first="Diana Gabriela" last="Iacob">Diana Gabriela Iacob</name><name sortKey="Iacob, Diana Gabriela" sort="Iacob, Diana Gabriela" uniqKey="Iacob D" first="Diana Gabriela" last="Iacob">Diana Gabriela Iacob</name><name sortKey="Iacob, Simona" sort="Iacob, Simona" uniqKey="Iacob S" first="Simona" last="Iacob">Simona Iacob</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000C66 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000C66 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32982720
|texte= SARS-CoV-2 Treatment Approaches: Numerous Options, No Certainty for a Versatile Virus.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32982720" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |